Benza Raymond L, Miller Dave P, Foreman Aimee J, Frost Adaani E, Badesch David B, Benton Wade W, McGoon Michael D
Allegheny General Hospital, Division of Cardiovascular Diseases, Pittsburgh, Pennsylvania.
ICON Clinical Research, San Francisco, California.
J Heart Lung Transplant. 2015 Mar;34(3):356-61. doi: 10.1016/j.healun.2014.09.016. Epub 2014 Sep 28.
Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a risk score calculator to predict 1-year survival. We evaluated prognostic implications of changes in the risk score and individual risk-score parameters over 12 months.
Patients were grouped by decreased, unchanged, or increased risk score from enrollment to 12 months. Kaplan-Meier estimates of subsequent 1-year survival were made based on change in the risk score during the initial 12 months of follow-up. Cox regression was used for multivariable analysis.
Of 2,529 patients in the analysis cohort, the risk score was decreased in 800, unchanged in 959, and increased in 770 at 12 months post-enrollment. Six parameters (functional class, systolic blood pressure, heart rate, 6-minute walk distance, brain natriuretic peptide levels, and pericardial effusion) each changed sufficiently over time to improve or worsen risk scores in ≥5% of patients. One-year survival estimates in the subsequent year were 93.7%, 90.3%, and 84.6% in patients with a decreased, unchanged, and increased risk score at 12 months, respectively. Change in risk score significantly predicted future survival, adjusting for risk at enrollment. Considering follow-up risk concurrently with risk at enrollment, follow-up risk was a much stronger predictor, although risk at enrollment maintained a significant effect on future survival.
Changes in REVEAL risk scores occur in most patients with pulmonary arterial hypertension over a 12-month period and are predictive of survival. Thus, serial risk score assessments can identify changes in disease trajectory that may warrant treatment modifications.
先前使用来自评估肺动脉高压疾病早期和长期管理登记处(REVEAL)的数据来开发一个风险评分计算器,以预测1年生存率。我们评估了12个月内风险评分及个体风险评分参数变化的预后意义。
根据从入组到12个月时风险评分降低、不变或升高对患者进行分组。基于随访最初12个月期间风险评分的变化,采用Kaplan-Meier法估计随后1年的生存率。采用Cox回归进行多变量分析。
在分析队列的2529例患者中,入组后12个月时,800例患者风险评分降低,959例患者风险评分不变,770例患者风险评分升高。六个参数(功能分级、收缩压、心率、6分钟步行距离、脑钠肽水平和心包积液)随时间变化足够大,足以使≥5%的患者风险评分改善或恶化。12个月时风险评分降低、不变和升高的患者,次年的1年生存率估计分别为93.7%、90.3%和84.6%。风险评分变化显著预测未来生存率,并对入组时的风险进行了校正。同时考虑随访风险和入组时的风险,随访风险是更强的预测因素,尽管入组时的风险对未来生存率仍有显著影响。
大多数肺动脉高压患者在12个月内REVEAL风险评分会发生变化,且可预测生存率。因此,连续的风险评分评估可识别疾病轨迹的变化,这可能需要调整治疗方案。